Cajal Neuroscience
- Founded: 2020
- Location: Seattle, WA
- Employee range: 11 - 50
- Clinical stage: RD
- Therapy area: neurodegenerative
- Drug types: NEU
- Product link: https://www.cajalneuro.com/science
- Funding: $96M A Nov 2022
- Investors: The Column Group, Lux Capital, Two Sigma Ventures, Evotec, Bristol Myers Squibb, Alexandria Venture Investments, Dolby Family Ventures
cajalneuro.com linkedin.com job board
Short description:
Neurodegenerative Therapies
Drug notes:
Contact us to add description: recruit@workinbiotech.com
Long description:
Cajal Neuroscience is developing drugs for neurodegenerative diseases. The complexity of the brain was uncovered by pioneering research by Santiago Ramón y Cajal, who illustrated his findings with hundreds of drawings. Inspired by his creativity, Cajal Neuroscience is researching how to model and treat complex diseases of the brain. By using a combination of high throughput microscopy, functional genetic screening and multi-omics approaches, Cajal can identify new drug targets for neurodegenerative diseases. To achieve success, Cajal will employ expertise from neurosurgeons, scientists and software engineers to generate and analyze high quality data.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com